NJ Court Shuts Down Suits Over Hormone Therapy Labeling

Law360, New York (September 29, 2011, 8:32 PM EDT) -- A New Jersey appeals court on Thursday affirmed the dismissal of a pair of tort suits accusing two Pfizer Inc. subsidiaries of failing to provide sufficient warning about the breast cancer risks tied to their hormone replacement therapy drugs.

In upholding a summary judgment ruling in favor of drug manufacturers Wyeth Inc. and Pharmacia & Upjohn Co., a three-judge panel ruled that the lower court had properly presumed that the warning labels for hormone replacement therapy treatments Premarin, Prempro and Provera were adequate.

“We affirm substantially...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.